Examkin

Soru

Zorluk: ZorInfectious Diseases

A 64-year-old man with a 15-year history of type 2 diabetes mellitus is evaluated in the outpatient clinic for a chronic ulcer on the plantar surface of his right great toe. Over the past 3 days, he has noted new-onset redness and mild pain surrounding the ulcer. He has not had fever, chills, or other systemic symptoms. He has no recent hospitalizations and has not received any antibiotics in the past year. Vital signs are temperature 37.0°C (98.6°F), blood pressure 135/85 mm Hg, heart rate 78/min, and respirations 14/min. Physical examination reveals a 1.5-cm, shallow ulcer on the plantar aspect of the right great toe. There is a 1-cm rim of blanching erythema surrounding the ulcer margins. There is no purulent drainage, fluctuance, or crepitus. The ulcer base does not probe to bone, and pedal pulses are palpable bilaterally. A superficial swab culture of the ulcer base obtained by a visiting home nurse 3 days ago shows heavy growth of methicillin-susceptible Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Initiate oral cephalexinCevap
  2. B
    Initiate oral ciprofloxacin and clindamycin
  3. C
    Initiate oral linezolid
  4. D
    Initiate oral amoxicillin-clavulanate and ciprofloxacin
  5. E
    Initiate intravenous piperacillin-tazobactam

Cevap

Initiate oral cephalexin.
The correct response recommends initiating a narrow-spectrum oral antibiotic. This patient presents with a mild diabetic foot infection (DFI), defined clinically by the presence of local inflammation (erythema >0.5 cm but ≤2 cm) without deeper tissue involvement or systemic signs. According to Infectious Diseases Society of America (IDSA) guidelines, mild, treatment-naive DFIs should be treated with narrow-spectrum oral antibiotics targeting aerobic Gram-positive cocci (Staphylococcus aureus and Streptococcus species). Appropriate agents include cephalexin, dicloxacillin, or amoxicillin-clavulanate. Although the superficial swab culture grew Pseudomonas aeruginosa, superficial cultures of chronic wounds are poorly correlated with deep tissue pathogens and frequently yield colonizing flora. Treating Pseudomonas is generally reserved for moderate to severe infections, patients with frequent water exposure to the wound, or those failing initial therapy. Therefore, providing narrow-spectrum coverage directed only at the MSSA and typical skin flora is the most appropriate management, adhering to principles of antimicrobial stewardship.

Adım Adım Çözüm

1
Classify the severity of the diabetic foot infection.
The infection is classified as mild.
The patient has local erythema of 1 cm (which is >0.5 cm but ≤2 cm), no involvement of deeper structures (does not probe to bone), and no systemic inflammatory response syndrome (SIRS) criteria.
2
Determine the appropriate empiric or targeted coverage for a mild diabetic foot infection.
Therapy should target aerobic Gram-positive cocci, specifically Staphylococcus aureus and Streptococcus species.
Current guidelines recommend narrow-spectrum oral agents for mild, treatment-naive diabetic foot infections.
3
Interpret the significance of the superficial wound culture results.
The MSSA is a likely pathogen, while the Pseudomonas aeruginosa represents colonization.
Superficial swabs of chronic wounds are notoriously unreliable and frequently capture colonizing flora. Pseudomonas rarely causes true tissue infection in mild diabetic foot ulcers unless there is a specific risk factor (e.g., heavy water exposure).
4
Select the most appropriate antibiotic regimen based on stewardship principles.
Cephalexin is selected.
It is a narrow-spectrum, oral beta-lactam that adequately covers the most likely true pathogens (MSSA and Streptococci) without indiscriminately broadening coverage for a colonizer.

Anahtar Kavram

In mild diabetic foot infections, antimicrobial therapy should strictly target Gram-positive cocci (MSSA and Streptococci); colonizers like Pseudomonas identified on superficial swabs should not be treated to maintain antibiotic stewardship.
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru